Abstract:BackgroundPathological cardiac hypertrophy occurs in response to numerous stimuli and precedes heart failure (HF). Therapies that ameliorate pathological cardiac hypertrophy are highly needed.MethodsThe expression level of miR-30d was analyzed in hypertrophy models and serum of patients with chronic heart failure by qRT-PCR. Gain and loss-of-function experiments of miR-30d were performed in vitro. miR-30d gain of function were performed in vivo. Bioinformatics, western blot, luciferase assay, qRT-PCR, and immunofluorescence were performed to examine the molecular mechanisms of miR-30d.FindingsmiR-30d was decreased in both murine and neonatal rat cardiomyocytes (NRCMs) models of hypertrophy. miR-30d overexpression ameliorated phenylephrine (PE) and angiotensin II (Ang II) induced hypertrophy in NRCMs, whereas the opposite phenotype was observed when miR-30d was downregulated. Consistently, the miR-30d transgenic rat was found to protect against isoproterenol (ISO)-induced pathological hypertrophy. Mechanistically, methyltransferase EZH2 could promote H3K27me3 methylation in the promotor region of miR-30d and suppress its expression during the pathological cardiac hypertrophy. miR-30d prevented pathological cardiac hypertrophy via negatively regulating its target genes MAP4K4 and GRP78 and inhibiting pro-hypertrophic nuclear factor of activated T cells (NFAT). Adeno-associated virus (AAV) serotype 9 mediated-miR-30d overexpression exhibited beneficial effects in murine hypertrophic model. Notably, miR-30d was reduced in serum of patients with chronic heart failure and miR-30d overexpression could significantly ameliorate pathological hypertrophy in human embryonic stem cell-derived cardiomyocytes.InterpretationOverexpression of miR-30d may be a potential approach to treat pathological cardiac hypertrophy.FundingThis work was supported by the grants from National Key Research and Development Project (2018YFE0113500 to J Xiao), National Natural Science Foundation of China (82020108002 to J Xiao, 81900359 to J Li), the grant from Science and Technology Commission of Shanghai Municipality (20DZ2255400 and 21XD1421300 to J Xiao, 22010500200 to J Li), Shanghai Sailing Program (19YF1416400 to J Li), the “Dawn” Program of Shanghai Education Commission (19SG34 to J Xiao), the “Chen Guang” project supported by the Shanghai Municipal Education Commission and Shanghai Education Development Foundation (19CG45 to J Li).

Inhibition of Mir-146B-5p Alleviates Isoprenaline-Induced Cardiac Hypertrophy Via Regulating DFCP1.

Cardiac Hypertrophy and Dysfunction Induced by Overexpression of Mir-214 in Vivo

MicroRNA-34c-5p Provokes Isoprenaline-Induced Cardiac Hypertrophy by Modulating Autophagy Via Targeting ATG4B

Mir-145 Inhibits Isoproterenol-Induced Cardiomyocyte Hypertrophy by Targeting the Expression and Localization of GATA6

Mir-421-mediated Suppression of FGF13 As a Novel Mechanism Ameliorates Cardiac Hypertrophy by Inhibiting Endoplasmic Reticulum Stress.

Mir-34A Modulates Angiotensin II-induced Myocardial Hypertrophy by Direct Inhibition of ATG9A Expression and Autophagic Activity.

MiRNA‐339‐5p Promotes Isoproterenol‐induced Cardiomyocyte Hypertrophy by Targeting VCP to Activate the Mtor Signaling

Mir-139-5p Inhibits Isoproterenol-Induced Cardiac Hypertrophy by Targetting C-Jun

Mir-96 Inhibits Cardiac Hypertrophy by Targeting Growth Factor Receptor-Bound 2.

Mir-218 Involvement in Cardiomyocyte Hypertrophy is Likely Through Targeting Rest

The Expression Of Microrna In Adult Rat Heart With Isoproterenol-Induced Cardiac Hypertrophy

Overexpression of Microrna-99a Attenuates Cardiac Hypertrophy

Overexpression of Microrna-26B Attenuates Angiotensin II-induced Cardiac Hypertrophy Through Inhibition of Autophagic Responses.

CDK6 Mediates the Effect of Attenuation of Mir-1 on Provoking Cardiomyocyte Hypertrophy

MiR-27a-3p/Hoxa10 Axis Regulates Angiotensin II-Induced Cardiomyocyte Hypertrophy by Targeting Kv4.3 Expression

Microrna-340-5p Functions Downstream Of Cardiotrophin-1 To Regulate Cardiac Eccentric Hypertrophy And Heart Failure Via Target Gene Dystrophin

Targeting Mir-30D Reverses Pathological Cardiac Hypertrophy

Long Noncoding RNA Myocardial Infarction‑associated Transcript is Associated with the Microrna‑150‑5p/p300 Pathway in Cardiac Hypertrophy.

Cardiomyocyte Overexpression of Mir-27B Induces Cardiac Hypertrophy and Dysfunction in Mice.

MicroRNA-378 suppresses myocardial fibrosis through a paracrine mechanism at the early stage of cardiac hypertrophy following mechanical stress.

miR‐31‐5p suppresses myocardial hypertrophy by targeting Nfatc2ip